CD19 CAR-T cell is named as a drug or biological intervention in 2 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) and Air Force Military Medical University, China (1). Registered phases: Phase 1/2 and Phase EARLY_PHASE1. Conditions studied include Systemic Lupus Erythematosus; Membranous Nephropathy; Lupus Nephritis (LN).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06106906 | A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus |
Phase 1/2 | Recruiting |
| NCT07535138 | Efficacy and Safety of CD19 CAR-ฮณฮด T Cells in the Treatment of Relapsed/Refractory Autoimmune Nephropathy (ClinicalTrials.gov ↗) Membranous Nephropathy, Lupus Nephritis (LN), IgA Nephropathy (IgAN) |
Phase EARLY_PHASE1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Systemic Lupus Erythematosus | 1 |
| Membranous Nephropathy | 1 |
| Lupus Nephritis (LN) | 1 |
| IgA Nephropathy (IgAN) | 1 |
| Lead sponsor | Trials |
|---|---|
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Air Force Military Medical University, China | 1 |
| Register | CD19 CAR-T cell trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how CD19 CAR-T cell works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists CD19 CAR-T cell (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.